Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06538987
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-08
Brief Title:
Anesthetic Management in Patients Undergoing Epicardial Ablation
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Anesthetic Management in Patients Undergoing Epicardial Ablation for the Treatment of Ventricular Tachycardia Retrospective Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is a retrospective study and is descriptive in nature In this study the investigators aimed to emphasize the importance of anesthesia management by cardiac risk assessment of patients undergoing epicardial ablation under general anesthesia and analysis of complications that developed during the procedure
Detailed Description:
The study is retrospective observational and data were collected by examining the files of all epicardial ablation patients received in the angiography unit starting from 30102020 until 30102022 after ethics committee approval is obtained Baseline characteristic features of the patients Sex Age years BMI kgm2 Hypertension Coronary artery disease COPD Chronic obstructive pulmonary disease CKD Chronic kidney disease Electrical storm and ventricular tachycardia etiology Ischemic cardiomyopathy Dilated cardiomyopathy the presence of ARVC Arrhythmogenic Right Ventricular Cardiomyopathy Hypertrophic cardiomyopathy will be recorded NHYA classification will be examined in two groups as NHYA I or II and NHYA III or IV also estimated glomerular filtration rate left ventricular ejection fraction PAAINESD acute hemodynamic decompensation risk assessment score iVT score Risk of VT recurrence Score information will be recorded Ventricular tachycardia focus locations dopamine dobutamine norepinephrine infusion requirement during the procedure arrest development during the procedure fluoroscopy time and ablation times will be recorded In the follow-up of the patients after the procedure Causes of death decompensated heart failure transient ischemic attack development of acute renal failure and recurrence of ventricular tachycardia will be recorded PAAINESD score acute hemodynamic decompensation risk assessment score will be recorded The PAAINESD Score developed to estimate the risk of periprocedural hemodynamic decompensation has values ranging from 0 to 35 points or 0 to 31 PAINESD when the modifiable intraprocedural variable general anesthesia is excluded duration of the procedure the need for inotropes during the procedure whether the patient needed mechanical ventilation after the procedure and the success rates after the procedure will be recorded
PAINESD Pulmonary disease chronic obstructive pulmonary disease 5 Age 60 years 3 Anaesthesia general 4 Ischaemic cardiomyopathy 6 NYHA class III or IV 6 Ejection fraction 25 3 Storm VT 5 Diabetes 3 Data will be analyzed in three separate categories the characteristics of the patients before the procedure during the procedure and after the procedure Descriptive tables and percentages of parameters will be created by statistical analysis
PAINESD Pulmonary disease chronic obstructive pulmonary disease 5 Age 60 years 3 Anaesthesia general 4 Ischaemic cardiomyopathy 6 NYHA class III or IV 6 Ejection fraction 25 3 Storm VT 5 Diabetes 3 Data will be analyzed in three separate categories the characteristics of the patients before the procedure during the procedure and after the procedure Descriptive tables and percentages of parameters will be created by statistical analysis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None